Shinichi Imamura Selected Research

Neoplasms (Cancer)

8/2020	New Series of Potent Allosteric Inhibitors of Deoxyhypusine Synthase.
1/2020	Discovery of Novel Allosteric Inhibitors of Deoxyhypusine Synthase.
1/2018	Discovery of novel serine palmitoyltransferase inhibitors as cancer therapeutic agents.
1/2017	A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
12/2013	Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
8/2013	Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics.
6/2013	A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
4/2013	Discovery of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593), a highly potent VEGFR2 kinase inhibitor.
4/2013	Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase.
12/2012	Design, synthesis, and evaluation of imidazo[1,2-b]pyridazine derivatives having a benzamide unit as novel VEGFR2 kinase inhibitors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shinichi Imamura Research Topics

Disease

14	Neoplasms (Cancer) 08/2020 - 10/2010
1	Neurodegenerative Diseases (Neurodegenerative Disease) 03/2024
1	Leukemia 01/2017
1	Carcinogenesis 06/2013
1	Adenocarcinoma of Lung 04/2013
1	Prostatic Neoplasms (Prostate Cancer) 10/2010
1	Stomach Neoplasms (Stomach Cancer) 12/2004

Drug/Important Bio-Agent (IBA)

4	Phosphotransferases (Kinase)IBA 12/2013 - 05/2012
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2013 - 12/2012
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2013 - 02/2011
2	LigandsIBA 03/2024 - 06/2013
2	hypusineIBA 08/2020 - 01/2020
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 12/2013 - 06/2013
2	PDGF receptor tyrosine kinaseIBA 04/2013 - 05/2012
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 05/2012 - 02/2011
1	Proteins (Proteins, Gene)FDA Link 03/2024
1	Protein Isoforms (Isoforms)IBA 03/2024
1	EnzymesIBA 08/2020
1	deoxyhypusine synthaseIBA 08/2020
1	Eukaryotic Translation Initiation Factor 5AIBA 08/2020
1	Oncogene Proteins (Oncogene Protein)IBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	ketodihydrosphingosineIBA 01/2018
1	Serine C-PalmitoyltransferaseIBA 01/2018
1	Lysine (L-Lysine)FDA Link 01/2017
1	N- (4- ((2- ((cyclopropylcarbonyl)amino)imidazo(1,2- a)pyridin- 6- yl)oxy)- 3- fluorophenyl)- 6- methyl- 2- oxo- 1- phenyl- 1,2- dihydropyridine- 3- carboxamideIBA 06/2013
1	Tyrosine (L-Tyrosine)FDA Link 06/2013
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 06/2013
1	Proto-Oncogene Proteins c-metIBA 06/2013
1	TAK 593IBA 04/2013
1	pyrimidineIBA 05/2012
1	Protein Kinases (Protein Kinase)IBA 02/2011
1	Oxygen (Dioxygen)IBA 02/2011
1	Dendrimers (Dendrons)IBA 01/2011
1	SaltsIBA 10/2010
1	titanium silicide (TS-1)IBA 12/2004

Therapy/Procedure

6	Oral Administration 01/2018 - 10/2010
3	Therapeutics 01/2018 - 12/2004